BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis 2020;71:1379-89. [PMID: 31606734 DOI: 10.1093/cid/ciz999] [Cited by in Crossref: 109] [Cited by in F6Publishing: 126] [Article Influence: 109.0] [Reference Citation Analysis]
Number Citing Articles
1 Emond B, Rossi C, Côté-sergent A, Dunn K, Lefebvre P, Lafeuille M, Donga P. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. JHEOR 2021;8:88-98. [DOI: 10.36469/jheor.2021.2435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hanttu A, Kauppinen KJ, Kivelä P, Ollgren J, Jousilahti P, Liitsola K, Koponen P, Sutinen J. Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population - missed diagnoses of diabetes? HIV Med 2021;22:244-53. [PMID: 33169536 DOI: 10.1111/hiv.13009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Isnard S, Lin J, Fombuena B, Ouyang J, Varin TV, Richard C, Marette A, Ramendra R, Planas D, Raymond Marchand L, Messaoudene M, Van der Ley CP, Kema IP, Sohail Ahmed D, Zhang Y, Finkelman M, Routy B, Angel J, Ancuta P, Routy JP. Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota. Open Forum Infect Dis 2020;7:ofaa338. [PMID: 32964062 DOI: 10.1093/ofid/ofaa338] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
4 Plum PE, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, Lecomte M, Léonard P, Paquot N, Fombellida K, Vaira D, Moutschen M, Darcis G. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis 2021;21:910. [PMID: 34488664 DOI: 10.1186/s12879-021-06479-9] [Reference Citation Analysis]
5 Hall N, Allavena C, Katlama C, Jobert A, Molina JM, Cua E, Bani-Sadr F, Hocqueloux L, Duvivier C, Merrien D, Hikombo H, André-Garnier E, Gaultier A, Raffi F; QDISS Study Group. Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial. AIDS Res Ther 2022;19:4. [PMID: 35033092 DOI: 10.1186/s12981-022-00428-5] [Reference Citation Analysis]
6 Pohlman FW, McGee KS, McKellar MS. Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. Open Forum Infect Dis 2021;8:ofab403. [PMID: 34430674 DOI: 10.1093/ofid/ofab403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pérez SE, Chow SP, Kania A, Goldberg R, Badowski ME. Weighing in on the Role of Integrase Strand Transfer Inhibitors (INSTIs) on Weight Gain: Fact or Fiction? Curr Infect Dis Rep 2020;22. [DOI: 10.1007/s11908-020-00727-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Raubinger S, Lee FJ, Pinto AN. HIV: the changing paradigm. Intern Med J 2022;52:542-9. [PMID: 35419962 DOI: 10.1111/imj.15739] [Reference Citation Analysis]
9 Bengtson AM, Phillips TK, le Roux SM, Brittain K, Zerbe A, Madlala HP, Malaba TR, Petro G, Abrams EJ, Myer L. High blood pressure at entry into antenatal care and birth outcomes among a cohort of HIV-uninfected women and women living with HIV initiating antiretroviral therapy in South Africa. Pregnancy Hypertens 2021;23:79-86. [PMID: 33285444 DOI: 10.1016/j.preghy.2020.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Venter WDF, Serenata C, Vitoria M, Mkhondwane L, Sikwese K, Pepperrell T, Clayden P, Qavi A, Doherty M, Penazzato M, Hill A. What we have learned from antiretroviral treatment optimization efforts over the last 5 years? AIDS 2021;35:S113-5. [PMID: 34848578 DOI: 10.1097/QAD.0000000000003081] [Reference Citation Analysis]
11 Fernandez-Botran R, Plankey MW, Ware D, Bordon J. Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers. Cytokine 2021;144:155573. [PMID: 33994069 DOI: 10.1016/j.cyto.2021.155573] [Reference Citation Analysis]
12 Stires H, LaMori J, Chow W, Zalewski Z, Vidulich A, Avina M, Sloan C, Hughes R 4th, Hardy H. Weight Gain and Related Comorbidities Following Antiretroviral Initiation in the 2000s: A Systematic Literature Review. AIDS Res Hum Retroviruses 2021;37:834-41. [PMID: 34541891 DOI: 10.1089/AID.2020.0216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Taramasso L, Bonfanti P, Ricci E, Maggi P, Orofino G, Squillace N, Menzaghi B, Madeddu G, Molteni C, Vichi F, Riguccini E, Saracino A, Santoro C, Guastavigna M, Francisci D, Di Biagio A, De Socio GV; CISAI study group. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. HIV Med 2021. [PMID: 34473897 DOI: 10.1111/hiv.13165] [Reference Citation Analysis]
14 Thivalapill N, Simelane T, Mthethwa N, Dlamini S, Lukhele B, Okello V, Kirchner HL, Mandalakas AM, Kay AW. Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis 2021;73:e580-6. [PMID: 33119739 DOI: 10.1093/cid/ciaa1652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lake JE, Trevillyan J. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS 2021;16:148-51. [PMID: 33797433 DOI: 10.1097/COH.0000000000000680] [Reference Citation Analysis]
16 Shoji K, Shirano M, Konishi M, Toyoshima Y, Matsumoto M, Goto T, Kasamatsu Y, Ichida Y, Kagawa Y, Kawabata T, Ogata H, Habu D. The Body Fat Percentage Rather Than the BMI Is Associated with the CD4 Count among HIV Positive Japanese Individuals. Nutrients 2022;14:428. [DOI: 10.3390/nu14030428] [Reference Citation Analysis]
17 Vuille-lessard É, Lange N, Riebensahm C, Dufour J, Berzigotti A. Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis. Curr Hepatology Rep 2021;20:61-76. [DOI: 10.1007/s11901-021-00563-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cadiñanos J, Montejano R, de Miguel Buckley R, Marcelo C, Arribas JR. Risks and benefits of reducing the number of drugs to treat HIV-1 infection. Expert Opin Drug Saf 2021;20:397-409. [PMID: 33557651 DOI: 10.1080/14740338.2021.1887135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hanttu A, Vuoti S, Kivelä P, Arkkila P, Lundbom N, Hakkarainen A, Lundbom J, Lehtimäki T, Viskari H, Lehtinen V, Pietiläinen KH, Sutinen J. Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. AIDS Patient Care STDS 2021;35:335-41. [PMID: 34524919 DOI: 10.1089/apc.2021.0106] [Reference Citation Analysis]
20 Shah S, Pilkington V, Hill A. Is tenofovir disoproxil fumarate associated with weight loss? AIDS 2021;35:S189-95. [PMID: 34848586 DOI: 10.1097/QAD.0000000000003083] [Reference Citation Analysis]
21 Goupil de Bouillé J, Vigouroux C, Plessis L, Ghislain M, Teglas JP, Boufassa F, Goujard C, Vignes D, Bouchaud O, Salmon D, Meyer L, Abgrall S; ANRS CO9-COPANA study group. Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers. J Infect Dis 2021;224:1570-80. [PMID: 33740044 DOI: 10.1093/infdis/jiab151] [Reference Citation Analysis]
22 Huang YS, Cheng CY, Liou BH, Lu PL, Cheng SH, Lee YT, Liu CE, Sun HY, Yang CJ, Tang HJ, Lin SP, Ho MW, Huang SH, Tsai HC, Lee CH, Hung CC; Taiwan HIV Study Group. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. J Acquir Immune Defic Syndr 2021;86:473-81. [PMID: 33273214 DOI: 10.1097/QAI.0000000000002589] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kileel EM, Dickins KA, Zheng H, Fitch KV, Looby SE. The Association of Distinct Social Determinants of Health with Added Sweetener Knowledge and Consumption in a U.S. Sample of People Living with HIV. AIDS Behav 2022;26:1552-61. [PMID: 34731406 DOI: 10.1007/s10461-021-03508-1] [Reference Citation Analysis]
24 Arant EC, Harding C, Geba M, Targonski PV, McManus KA. Human Immunodeficiency Virus (HIV) and Aging: Multimorbidity in Older People With HIV in One Nonurban Southeastern Ryan White HIV/AIDS Program Clinic. Open Forum Infect Dis 2021;8:ofaa584. [PMID: 33511226 DOI: 10.1093/ofid/ofaa584] [Reference Citation Analysis]
25 Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, Overton ET, Okeke NL, Kumar P, Joao E, Aberg JA, Martinez E, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab537. [PMID: 34888395 DOI: 10.1093/ofid/ofab537] [Reference Citation Analysis]
26 Taramasso L, Stapleton JT, Siedner MJ. Weight gain and aging in people with HIV. AIDS 2021;35:987-9. [PMID: 33821824 DOI: 10.1097/QAD.0000000000002849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 McMahon C, Trevaskis JL, Carter C, Holsapple K, White K, Das M, Collins S, Martin H, Burns-Naas LA. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight. PLoS One 2020;15:e0229617. [PMID: 32109250 DOI: 10.1371/journal.pone.0229617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
28 Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Garcia JM, Dong Y, Richardson P, Kramer JR, Hartman CM, Royse K, White DL, Chiao EY. Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV. HIV Med 2022. [PMID: 35929183 DOI: 10.1111/hiv.13366] [Reference Citation Analysis]
30 Ibrahim F, Samarawickrama A, Hamzah L, Vincent R, Gilleece Y, Waters L, Kegg S, Barbini B, Campbell L, Post FA; BESTT Trial Team. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG. HIV Med 2021;22:83-91. [PMID: 32985122 DOI: 10.1111/hiv.12961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Hamooya BM, Mulenga LB, Masenga SK, Fwemba I, Chirwa L, Siwingwa M, Halwiindi H, Koethe JR, Lipworth L, Heimburger DC, Musonda P, Mutale W. Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: Prevalence and associated factors. Medicine (Baltimore) 2021;100:e25236. [PMID: 33832083 DOI: 10.1097/MD.0000000000025236] [Reference Citation Analysis]
32 Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, Berenguer J, D'Antoni ML, Blair C, Chuck SK, Piontkowsky D, Martin H, Haubrich R, McNicholl IR, Gallant J. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infect Dis Ther 2021;10:775-88. [PMID: 33686573 DOI: 10.1007/s40121-021-00419-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, Wohlfeiler MB. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infect Dis 2022;9:ofab621. [PMID: 35028335 DOI: 10.1093/ofid/ofab621] [Reference Citation Analysis]
34 Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Wang H, Liu Y, Wei X, White K, Makadzange T, Pikora C, McNicholl I, Collins SE, Brainard D, Chuck SK. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. J Acquir Immune Defic Syndr 2021;88:393-8. [PMID: 34506342 DOI: 10.1097/QAI.0000000000002789] [Reference Citation Analysis]
35 Choi JY, Lui GCY, Liao CT, Yang CJ. Managing cardiovascular risk in people living with HIV in Asia - where are we now? HIV Med 2021. [PMID: 34494350 DOI: 10.1111/hiv.13164] [Reference Citation Analysis]
36 Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication. Curr Opin HIV AIDS 2021;16:106-14. [PMID: 33625041 DOI: 10.1097/COH.0000000000000671] [Reference Citation Analysis]
37 Diggins CE, Russo SC, Lo J. Metabolic Consequences of Antiretroviral Therapy. Curr HIV/AIDS Rep 2022. [PMID: 35299263 DOI: 10.1007/s11904-022-00600-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Siedner MJ, Moorhouse MA, Simmons B, de Oliveira T, Lessells R, Giandhari J, Kemp SA, Chimukangara B, Akpomiemie G, Serenata CM, Venter WDF, Hill A, Gupta RK. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nat Commun 2020;11:5922. [PMID: 33262331 DOI: 10.1038/s41467-020-19801-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
39 Turvey SL, Saxinger L, Mason AL. Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis. Viruses 2022;14:516. [DOI: 10.3390/v14030516] [Reference Citation Analysis]
40 Williams C, Kamau FM, Everson F, Kgokane B, De Boever P, Goswami N, Webster I, Strijdom H. HIV and Antiretroviral Therapy Are Independently Associated with Cardiometabolic Variables and Cardiac Electrical Activity in Adults from the Western Cape Region of South Africa. J Clin Med 2021;10:4112. [PMID: 34575223 DOI: 10.3390/jcm10184112] [Reference Citation Analysis]
41 Calza L, Borderi M, Colangeli V, Esposito F, Giglia M, Bon I, Re MC. Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine. AIDS Res Hum Retroviruses 2021;37:11-5. [PMID: 32935552 DOI: 10.1089/AID.2020.0167] [Reference Citation Analysis]
42 Chang HM, Chou PY, Chou CH, Tsai HC. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Infect Drug Resist 2021;14:4877-86. [PMID: 34853517 DOI: 10.2147/IDR.S331647] [Reference Citation Analysis]
43 Wood BR, Huhn GD. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? Open Forum Infect Dis 2021;8:ofab542. [PMID: 34877366 DOI: 10.1093/ofid/ofab542] [Reference Citation Analysis]
44 Adrian S, Miao H, Feng H, Scherzinger A, Nardini G, Beghetto B, Roncaglia E, Ligabue G, Milic J, Guaraldi G, Lake JE, Erlandson KM. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV. HIV Res Clin Pract 2020;21:91-8. [PMID: 32878571 DOI: 10.1080/25787489.2020.1809807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31431-2. [PMID: 33069882 DOI: 10.1016/j.cgh.2020.10.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
46 Lopez-Alvarenga JC, Martinez DA, Diaz-Badillo A, Morales LD, Arya R, Jenkinson CP, Curran JE, Lehman DM, Blangero J, Duggirala R, Mummidi S, Martinez RD. Association of HIV-1 Infection and Antiretroviral Therapy With Type 2 Diabetes in the Hispanic Population of the Rio Grande Valley, Texas, USA. Front Med (Lausanne) 2021;8:676979. [PMID: 34291061 DOI: 10.3389/fmed.2021.676979] [Reference Citation Analysis]
47 Erlandson KM, Wu K, Lake JE, Samuels DC, Bares SH, Tassiopoulos K, Koethe JR, Brown TT, Leonard M, Benson CA, Haas DW, Hulgan T; A5001, A5322 Protocol Teams. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. AIDS 2021;35:439-45. [PMID: 33252493 DOI: 10.1097/QAD.0000000000002771] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Rossi C, Côté-sergent A, Dunn K, Lefebvre P, Lafeuille M, Donga P, Emond B. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. JHEOR 2021;8:88-98. [DOI: 10.36469/jheor.2021.24535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Alebel A, Demant D, Petrucka PM, Sibbritt D. Weight change after antiretroviral therapy initiation among adults living with HIV in Northwest Ethiopia: a longitudinal data analysis. BMJ Open 2022;12:e055266. [PMID: 35105589 DOI: 10.1136/bmjopen-2021-055266] [Reference Citation Analysis]
50 Yendewa GA, Perez JA, Schlick K, Tribout H, McComsey GA. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX). Open Forum Infect Dis 2021;8:ofab272. [PMID: 34435074 DOI: 10.1093/ofid/ofab272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Hsu R, Brunet L, Fusco JS, Mounzer K, LaMori J, Fusco GP. Excessive weight gain: current antiretroviral agents in virologically suppressed people with HIV. AIDS Res Hum Retroviruses 2022. [PMID: 35923143 DOI: 10.1089/AID.2021.0188] [Reference Citation Analysis]
52 Pond RA, Collins LF, Lahiri CD. Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab558. [PMID: 34888399 DOI: 10.1093/ofid/ofab558] [Reference Citation Analysis]
53 Kanda N, Okamoto K, Okumura H, Mieno M, Sakashita K, Sasahara T, Hatakeyama S. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. HIV Med 2021;22:457-66. [PMID: 33720508 DOI: 10.1111/hiv.13061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Lazzaro A, Cacciola EG, Borrazzo C, Innocenti GP, Cavallari EN, Mezzaroma I, Falciano M, Fimiani C, Mastroianni CM, Ceccarelli G, d’Ettorre G. Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics 2022;12:76. [DOI: 10.3390/diagnostics12010076] [Reference Citation Analysis]
55 Musekwa R, Hamooya BM, Koethe JR, Nzala S, Masenga SK. Prevalence and correlates of hypertension in HIV-positive adults from the Livingstone Central Hospital, Zambia. Pan Afr Med J 2021;39:237. [PMID: 34659610 DOI: 10.11604/pamj.2021.39.237.29718] [Reference Citation Analysis]
56 Squillace N, Ricci E, Menzaghi B, De Socio GV, Passerini S, Martinelli C, Mameli MS, Maggi P, Falasca K, Cordier L, Celesia BM, Salomoni E, Di Biagio A, Pellicanò GF, Bonfanti P; CISAI Study Group. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile. Drug Des Devel Ther 2020;14:5515-20. [PMID: 33364747 DOI: 10.2147/DDDT.S274307] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, Damond F, Descamps D, Yazdanpanah Y, Peytavin G, Ghosn J. Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection. J Antimicrob Chemother 2021:dkab192. [PMID: 34109414 DOI: 10.1093/jac/dkab192] [Reference Citation Analysis]
58 Savinelli S, De Francesco D, Feeney ER, Babalis D, Bagkeris E, Post FA, Boffito M, Williams I, Vera J, Johnson M, Anderson J, Sachikonye M, Winston A, Sabin C, Mallon P. Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. HIV Med 2020;21:441-52. [PMID: 32311831 DOI: 10.1111/hiv.12857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yendewa GA, Lakoh S, Jiba DF, Yendewa SA, Barrie U, Deen GF, Samai M, Jacobson JM, Sahr F, Salata RA. Hepatitis B Virus and Tuberculosis Are Associated with Increased Noncommunicable Disease Risk among Treatment-Naïve People with HIV: Opportunities for Prevention, Early Detection and Management of Comorbidities in Sierra Leone. J Clin Med 2022;11:3466. [PMID: 35743539 DOI: 10.3390/jcm11123466] [Reference Citation Analysis]
60 O'Halloran JA, Sahrmann J, Parra-Rodriguez L, Vo DT, Butler AM, Olsen MA, Powderly WG. Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV. Clin Infect Dis 2022:ciac355. [PMID: 35521785 DOI: 10.1093/cid/ciac355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Bonou M, Kapelios CJ, Protogerou AD, Mavrogeni S, Aggeli C, Markousis-Mavrogenis G, Psichogiou M, Barbetseas J. Cardiac adiposity as a modulator of cardiovascular disease in HIV. HIV Med 2021;22:879-91. [PMID: 34514685 DOI: 10.1111/hiv.13166] [Reference Citation Analysis]
62 Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol 2019;12:1129-43. [PMID: 31774001 DOI: 10.1080/17512433.2019.1698946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
63 Michienzi SM, Johnson M, Chiampas TD, Wenzler E, Burgos RM, Smith RO, Badowski ME. Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Drugs Context 2021;10:2021-2-1. [PMID: 34349820 DOI: 10.7573/dic.2021-2-1] [Reference Citation Analysis]
64 Rethy L, Feinstein MJ, Sinha A, Achenbach C, Shah SJ. Coronary Microvascular Dysfunction in HIV: A Review. J Am Heart Assoc 2020;9:e014018. [PMID: 31852423 DOI: 10.1161/JAHA.119.014018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Lahiri CD, Xu Y, Wang K, Alvarez JA, Sheth AN, O'Halloran J, Spence AB, Tien P, Gustafson DR, Milam J, Fischl MA, Konkle-Parker D, Adimora AA, Sharma A, Weber KM, Ofotokun I, Rubin LH. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV. AIDS Res Hum Retroviruses 2021;37:461-7. [PMID: 33231474 DOI: 10.1089/AID.2020.0197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
66 Courlet P, Barbieux C, Sculier D, Wandeler G, Stoeckle M, Bernasconi E, Braun D, Vernazza P, Cavassini M, Marinosci A, Smit M, Günthard HF, Schmid P, Limacher A, Guidi M, Alves Saldanha S, Decosterd LA, Calmy A. Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. Br J Clin Pharmacol 2021. [PMID: 33764567 DOI: 10.1111/bcp.14832] [Reference Citation Analysis]
67 Masters MC, Cohn SE. Two-drug HIV regimens: more data still needed. Lancet HIV 2021;8:e454-5. [PMID: 34358493 DOI: 10.1016/S2352-3018(21)00106-5] [Reference Citation Analysis]
68 Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV 2021;8:e185-96. [PMID: 33794181 DOI: 10.1016/S2352-3018(20)30340-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
69 Emond B, Rossi C, Côté-Sergent A, Dunn K, Lefebvre P, Lafeuille MH, Donga P. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. J Health Econ Outcomes Res 2021;8:88-98. [PMID: 34179212 DOI: 10.36469/001c.24535] [Reference Citation Analysis]
70 Rodés B, Cadiñanos J, Esteban-Cantos A, Rodríguez-Centeno J, Arribas JR. Ageing with HIV: Challenges and biomarkers. EBioMedicine 2022;77:103896. [PMID: 35228014 DOI: 10.1016/j.ebiom.2022.103896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Koay WLA, Dirajlal-Fargo S, Levy ME, Kulie P, Monroe A, Castel AD, Rakhmanina NY; DC Cohort Executive Committee . Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort. Open Forum Infect Dis 2021;8:ofab308. [PMID: 34295943 DOI: 10.1093/ofid/ofab308] [Reference Citation Analysis]
72 Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis 2020;222:S63-9. [PMID: 32645158 DOI: 10.1093/infdis/jiaa245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
73 Chen IW, Sun HY, Hung CC. Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV. Infect Dis Ther 2021;10:1331-46. [PMID: 33977505 DOI: 10.1007/s40121-021-00449-z] [Reference Citation Analysis]
74 Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs 2020;80:1649-76. [PMID: 32860583 DOI: 10.1007/s40265-020-01379-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
75 Kline MDA, Daniels C, Xu X, Sunil T, Ganesan A, Agan BK, Colombo RE, Kronmann KC, Blaylock JM, Okulicz JF, Markelz AE. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV. Mil Med 2021;186:279-85. [PMID: 33128552 DOI: 10.1093/milmed/usaa416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rodriguez-Gonzalez CG, Chamorro-de-Vega E, Ortega-Navarro C, Alonso R, Herranz-Alonso A, Sanjurjo-Saez M. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients. Ann Pharmacother 2020;54:633-43. [PMID: 31910643 DOI: 10.1177/1060028019896638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Darnell J, Jain S, Sun X, Qin H, Reynolds T, Karris MY, Hill LA. Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen. Medicine (Baltimore) 2021;100:e27047. [PMID: 34449491 DOI: 10.1097/MD.0000000000027047] [Reference Citation Analysis]
78 Hongo H, Nagao T, Nakamura K, Kitaichi T, Maeno Y, Tokunaga T, Fukuda A, Koga I. Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan. Adv Ther 2021;38:4480-504. [PMID: 34275116 DOI: 10.1007/s12325-021-01842-3] [Reference Citation Analysis]
79 Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P. Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States. J Health Econ Outcomes Res 2022;9:39-49. [PMID: 35233432 DOI: 10.36469/jheor.2022.31825] [Reference Citation Analysis]
80 Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, Peng L, Xie C. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. Antiviral Therapy 2022;27:135965352210823. [DOI: 10.1177/13596535221082399] [Reference Citation Analysis]
81 Stockdale AJ, Khoo S. Doravirine: its role in HIV treatment. Curr Opin HIV AIDS 2022;17:4-14. [PMID: 34740228 DOI: 10.1097/COH.0000000000000709] [Reference Citation Analysis]
82 Antela A, Rivero A, Llibre JM, Moreno S; RET Group . Redefining therapeutic success in HIV patients: an expert view. J Antimicrob Chemother 2021:dkab168. [PMID: 34077524 DOI: 10.1093/jac/dkab168] [Reference Citation Analysis]
83 Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S, Thiagarajah S, Van Solingen-Ristea R, Ford SL, Crauwels H, Patel P, Cutrell A, Smith KY, Vandermeulen K, Birmingham E, St Clair M, Spreen WR, D'Amico R. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV 2021;8:e668-78. [PMID: 34656207 DOI: 10.1016/S2352-3018(21)00184-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Maragh-Bass AC, Parker S, Thompson G, Erlandson KM, Karris M, Webster J, White BL. 'Ending the HIV epidemic': where are African American women in the plan? AIDS 2021;35:2541-4. [PMID: 34870932 DOI: 10.1097/QAD.0000000000003037] [Reference Citation Analysis]
85 Debroy P, Feng H, Miao H, Milic J, Ligabue G, Draisci S, Besutti G, Carli F, Menozzi M, Mussini C, Guaraldi G, Lake JE. Changes in central adipose tissue after switching to integrase inhibitors. HIV Res Clin Pract 2020;21:168-73. [PMID: 33459579 DOI: 10.1080/25787489.2020.1848131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Koethe JR, Moser C, Brown TT, Stein JH, Kelesidis T, Dube M, Currier J, McComsey GA. Adipokines, Weight Gain and Metabolic and Inflammatory Markers after Antiretroviral Therapy Initiation: ACTG A5260s. Clin Infect Dis 2021:ciab542. [PMID: 34117756 DOI: 10.1093/cid/ciab542] [Reference Citation Analysis]
87 Liu D, Shen Y, Zhang R, Xun J, Wang J, Liu L, Steinhart C, Chen J, Lu H. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. J Gastroenterol Hepatol 2021;36:1670-8. [PMID: 33140878 DOI: 10.1111/jgh.15320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Ponatshego PL, Youssouf NF, Mosepele M. Current co-morbidities burden in patients living with HIV in low- and middle-income countries. Curr Opin HIV AIDS 2021;16:163-7. [PMID: 33833207 DOI: 10.1097/COH.0000000000000676] [Reference Citation Analysis]
89 Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV 2021;8:e679-89. [PMID: 34648734 DOI: 10.1016/S2352-3018(21)00185-5] [Reference Citation Analysis]
90 Huang S, Huang W, Lin S, Chuang Y, Sun H, Chang S, Kuo P, Wu P, Liu W, Chiang C, Hung C, Chang S. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 2021;87:834-41. [DOI: 10.1097/qai.0000000000002650] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers 2020;6:48. [PMID: 32555389 DOI: 10.1038/s41572-020-0181-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
92 Podzamczer D, Micán R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masiá M, Gómez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro Á, Bernal E, Vinuesa D, Knobel H, Troya J, Macías J, Montero M, Sanz J, Navarro-alcaraz A, Caicedo A, Fernández G, Martínez E, Moreno S. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases 2022;9:ofab595. [DOI: 10.1093/ofid/ofab595] [Reference Citation Analysis]
93 Sinha A, Feinstein MJ. Immune Dysregulation in Myocardial Fibrosis, Steatosis, and Heart Failure: Current Insights from HIV and the General Population. Curr HIV/AIDS Rep 2021;18:63-72. [PMID: 33433816 DOI: 10.1007/s11904-020-00536-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Lee YL, Lin KY, Cheng SH, Lu PL, Wang NC, Ho MW, Yang CJ, Liou BH, Tang HJ, Huang SS, Huang SH, Chen TC, Lin CY, Lin SP, Lee YT, Hung CC; Taiwan HIV Study Group. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV. Int J Antimicrob Agents 2021;58:106403. [PMID: 34289404 DOI: 10.1016/j.ijantimicag.2021.106403] [Reference Citation Analysis]
95 Esber AL, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J, Singoei V, Maswai J, Dear NF, Crowell TA, Polyak CS, Ake JA; AFRICOS Study Group. Weight gain during the dolutegravir transition in the African Cohort Study. J Int AIDS Soc 2022;25:e25899. [PMID: 35419973 DOI: 10.1002/jia2.25899] [Reference Citation Analysis]
96 Dirajlal-Fargo S, McComsey GA. Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy. Curr HIV/AIDS Rep 2021;18:424-35. [PMID: 34652624 DOI: 10.1007/s11904-021-00574-x] [Reference Citation Analysis]
97 Venter WDF, Hill A. Weighing considerations with newer antiretrovirals. Lancet HIV 2020;7:e374-5. [PMID: 32504568 DOI: 10.1016/S2352-3018(20)30115-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Smith SJ, Zhao XZ, Passos DO, Lyumkis D, Burke TR Jr, Hughes SH. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. Viruses 2021;13:205. [PMID: 33572956 DOI: 10.3390/v13020205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Domingo P, Villarroya F, Giralt M, Domingo JC. Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. Int J Obes (Lond) 2020;44:1970-3. [PMID: 32080347 DOI: 10.1038/s41366-020-0551-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
100 Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, Horberg MA, Matthews WC, Silverberg MJ, Thorne J, Mayor AM, Lima VD, Palella FJ, Saag MS, Althoff KN, Gill MJ, Wong C, Klein MB, Crane HM, Marconi VC, Shepherd BE, Sterling TR, Koethe JR. Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada. Clin Infect Dis 2020:ciaa1403. [PMID: 32936919 DOI: 10.1093/cid/ciaa1403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
101 van Wyk J, Ait-Khaled M, Santos J, Scholten S, Wohlfeiler M, Ajana F, Jones B, Nascimento MC, Tenorio AR, Smith DE, Wright J, Wynne B. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. J Acquir Immune Defic Syndr 2021;87:794-800. [PMID: 33587500 DOI: 10.1097/QAI.0000000000002655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Sarkar S, Brown TT. Diabetes in People with HIV. Curr Diab Rep 2021;21:13. [PMID: 33730223 DOI: 10.1007/s11892-021-01382-8] [Reference Citation Analysis]
103 Yeoh DK, Campbell AJ, Bowen AC. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens. Pediatric Infectious Disease Journal 2021;40:e215-6. [DOI: 10.1097/inf.0000000000003076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Verboeket SO, Boyd A, Wit FW, Verheij E, Schim van der Loeff MF, Kootstra N, van der Valk M, Reiss P; AGEhIV Cohort Study Group. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants. PLoS One 2021;16:e0251205. [PMID: 33951089 DOI: 10.1371/journal.pone.0251205] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Macaluso F, Gustafson DR. Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV. J AIDS HIV Treat 2021;3:21-3. [PMID: 34291233 DOI: 10.33696/AIDS.3.016] [Reference Citation Analysis]
106 Scévola S, Tiraboschi JM, Podzamczer D. Nothing is perfect: the safety issues of integrase inhibitor regimens. Expert Opin Drug Saf 2020;19:683-94. [PMID: 32356477 DOI: 10.1080/14740338.2020.1764531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
107 Papot E, Kaplan R, Vitoria M, Polizzotto MN. Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective. AIDS 2021;35:S153-63. [PMID: 34848582 DOI: 10.1097/QAD.0000000000003108] [Reference Citation Analysis]
108 Asundi A, Olson A, Jiang W, Varshney SP, White LF, Sagar M, Lin NH. Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus. AIDS Res Hum Retroviruses 2022;38:208-15. [PMID: 34877881 DOI: 10.1089/AID.2021.0091] [Reference Citation Analysis]
109 Chen YW, Hardy H, Pericone CD, Chow W. Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors. J Health Econ Outcomes Res 2020;7:102-10. [PMID: 32766375 DOI: 10.36469/jheor.2020.13457] [Reference Citation Analysis]
110 Wu KS, Anderson C, Little SJ. Integrase Strand Transfer Inhibitors Play the Main Role in Greater Weight Gain Among Men With Acute and Early HIV Infection. Open Forum Infect Dis 2021;8:ofaa619. [PMID: 33511237 DOI: 10.1093/ofid/ofaa619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Ciccullo A, Baldin G, Putaggio C, Di Giambenedetto S, Borghetti A. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV. Expert Opin Drug Saf 2021;:1-16. [PMID: 34018892 DOI: 10.1080/14740338.2021.1931115] [Reference Citation Analysis]
112 Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Ann Intern Med 2020;172:583-90. [PMID: 32150602 DOI: 10.7326/M19-3478] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
113 Farinacci D, Ciccullo A, Lombardi F, Moschese D, D’angelillo A, Iannone V, Lamanna F, Passerotto RA, Giambenedetto SD. Evaluation of doravirine-based regimen population target in a large Italian clinical center. Antiviral Therapy 2021;26:79-83. [DOI: 10.1177/13596535211056556] [Reference Citation Analysis]
114 Psomas CK, Kinloch S. Highlights of the 17th European AIDS Clinical Society (EACS) Conference, 6–9 November 2019, Basel, Switzerland. Journal of Virus Eradication 2020;6:38-43. [DOI: 10.1016/s2055-6640(20)30010-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Cohn J, Ake J, Moorhouse M, Godfrey C. Sex Differences in the Treatment of HIV. Curr HIV/AIDS Rep 2020;17:373-84. [PMID: 32529349 DOI: 10.1007/s11904-020-00499-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Frange P, Avettand‐fenoel V, Veber F, Blanche S. No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort. HIV Medicine. [DOI: 10.1111/hiv.13302] [Reference Citation Analysis]
117 Taramasso L, Bonfanti P, Ricci E, Orofino G, Squillace N, Menzaghi B, De Socio GV, Madeddu G, Pellicanò GF, Pagnucco L, Celesia BM, Calza L, Conti F, Martinelli CV, Valsecchi L, Cascio A, Bolla C, Maggi P, Vichi F, Dentone C, Angioni G, Mastroianni A, Falasca K, Cenderello G, Di Biagio A. Factors Associated With Weight Gain in People Treated With Dolutegravir. Open Forum Infect Dis 2020;7:ofaa195. [PMID: 32577427 DOI: 10.1093/ofid/ofaa195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
118 Kuber A, Reuter A, Geldsetzer P, Chimbindi N, Moshabela M, Tanser F, Bärnighausen T, Vollmer S. The effect of eligibility for antiretroviral therapy on body mass index and blood pressure in KwaZulu-Natal, South Africa. Sci Rep 2021;11:14718. [PMID: 34282184 DOI: 10.1038/s41598-021-94057-z] [Reference Citation Analysis]
119 Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489., GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV 2020;7:e389-400. [PMID: 32504574 DOI: 10.1016/S2352-3018(20)30099-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
120 Domínguez-Riscart J, Soria-Alcaide E, Mellado MJ, Sainz T. The Issue of Body Mass Index Increase in Adolescents Living With HIV on ART. Pediatr Infect Dis J 2021;40:e319-21. [PMID: 34250982 DOI: 10.1097/INF.0000000000003175] [Reference Citation Analysis]
121 Kovari H, Surial B, Tarr PE, Cavassini M, Calmy A, Schmid P, Bernasconi E, Rauch A, Wandeler G, Ledergerber B; Swiss HIV Cohort Study. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. HIV Med 2021;22:623-8. [PMID: 33880839 DOI: 10.1111/hiv.13106] [Reference Citation Analysis]
122 Cirrincione LR, Senneker T, Scarsi K, Tseng A. Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals. Expert Opin Drug Metab Toxicol 2020;16:565-82. [PMID: 32479127 DOI: 10.1080/17425255.2020.1777278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
123 Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martínez E; DOLAM study group. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV 2021;8:e463-73. [PMID: 34358497 DOI: 10.1016/S2352-3018(21)00100-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Ozemek C, Erlandson KM, Jankowski CM. Physical activity and exercise to improve cardiovascular health for adults living with HIV. Prog Cardiovasc Dis 2020;63:178-83. [PMID: 32014512 DOI: 10.1016/j.pcad.2020.01.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
125 Giacomet V, Lazzarin S, Manzo A, Paradiso L, Maruca K, Barera G, Zuccotti GV, Mora S. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir. Pediatric Infectious Disease Journal 2021;40:457-9. [DOI: 10.1097/inf.0000000000003066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Sørensen EW, Gelpi M, Knudsen AD, Benfield T, Mocroft A, Nielsen SD. Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV. J Acquir Immune Defic Syndr 2021;88:e36-8. [PMID: 34520441 DOI: 10.1097/QAI.0000000000002802] [Reference Citation Analysis]
127 Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, Gill J, Rabkin CS, Gange SJ, Horberg MA, Margolick J, Li J, Wong C, Willig A, Lima VD, Crane H, Thorne J, Silverberg M, Kirk G, Mathews WC, Sterling TR, Lake J, Koethe JR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc 2020;23:e25484. [PMID: 32294337 DOI: 10.1002/jia2.25484] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
128 The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS 2021;35:869-82. [PMID: 33443370 DOI: 10.1097/QAD.0000000000002811] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
129 Hamzah L, Post FA. Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir. AIDS 2021;35:349-51. [PMID: 33394676 DOI: 10.1097/QAD.0000000000002742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, Beyer AP, Wohlfeiler MB, Fusco GP. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc 2021;24:e25702. [PMID: 33838004 DOI: 10.1002/jia2.25702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
131 Kuo PH, Sun HY, Chuang YC, Wu PY, Liu WC, Hung CC. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Int J Infect Dis 2020;92:71-7. [PMID: 31884172 DOI: 10.1016/j.ijid.2019.12.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
132 Calza L, Colangeli V, Borderi M, Beci G, Esposito F, Bon I, Re MC, Viale P. Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. Infect Dis (Lond) 2021;53:81-8. [PMID: 32955957 DOI: 10.1080/23744235.2020.1823468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Panza E, Lillis J, Olson K, van den Berg JJ, Tashima K, Wing RR. HIV Status, Obesity, and Risk for Weight Stigma: Comparing Weight Stigma Experiences and Internalization Among Adults with Obesity with and Without HIV. AIDS Behav 2022;26:686-97. [PMID: 34396464 DOI: 10.1007/s10461-021-03428-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Selvaraj SV, Bares SH, Havens JP. Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis. Open Forum Infect Dis 2020;7:ofaa454. [PMID: 33134420 DOI: 10.1093/ofid/ofaa454] [Reference Citation Analysis]
135 Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, Spagnuolo V, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Med 2022. [PMID: 35233903 DOI: 10.1111/hiv.13273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Mauss S, Boesecke C. Communicable and noncommunicable liver disease in HIV. Curr Opin HIV AIDS 2021;16:152-5. [PMID: 33783404 DOI: 10.1097/COH.0000000000000675] [Reference Citation Analysis]
137 Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS 2021;35:S117-25. [PMID: 34261099 DOI: 10.1097/QAD.0000000000003020] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
138 Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, Smith DM, Benson CA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA 2020;324:1651-69. [PMID: 33052386 DOI: 10.1001/jama.2020.17025] [Cited by in Crossref: 132] [Cited by in F6Publishing: 95] [Article Influence: 66.0] [Reference Citation Analysis]
139 Mounzer K, Brunet L, Hsu R, Fusco J, Vannappagari V, Henegar C, van Wyk J, Crawford M, Lo J, Fusco G. Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Res Hum Retroviruses 2021;37:852-61. [PMID: 34002626 DOI: 10.1089/AID.2020.0287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Umbleja T, Brown TT, Overton ET, Ribaudo HJ, Schrack JA, Fitch KV, Douglas PS, Grinspoon SK, Henn S, Arduino RC, Rodriguez B, Benson CA, Erlandson KM. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. J Infect Dis 2020;222:S52-62. [PMID: 32645163 DOI: 10.1093/infdis/jiaa249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
141 Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Sekwese K, Mashabane N, Pozniak A, Khoo S, Ali M, Delaporte E, Lalla-Edwards S, Clayden P, Marconi VC, Siedner MJ, Boffito M, Serenata C, Carman M, Collins S. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS 2021;35:S183-8. [PMID: 34848585 DOI: 10.1097/QAD.0000000000003092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Nasreddine R, Yombi JC, Darcis G, Florence E, Allard SD, De Scheerder MA, Henrard S, Demeester R, Messiaen P, Ausselet N, Loeckx M, Delforge M, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH). Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium. HIV Med 2022. [PMID: 35938381 DOI: 10.1111/hiv.13373] [Reference Citation Analysis]
143 Bares SH, Smeaton LM, Scott SE, Smith BA, Godfrey C, McComsey GA. The Association Between Weight Gain, Sex and Immune Activation Following the Initiation of Antiretroviral Therapy. J Infect Dis 2021:jiab210. [PMID: 33870433 DOI: 10.1093/infdis/jiab210] [Reference Citation Analysis]
144 Han WM, Law MG, Choi JY, Ditangco R, Kumarasamy N, Chaiwarith R, Ly PS, Khusuwan S, Merati TP, Do CD, Yunihastuti E, Azwa I, Lee MP, Pham TN, Chan YJ, Kiertiburanakul S, Ng OT, Tanuma J, Pujari S, Zhang F, Gani Y, Mave V, Ross J, Avihingsanon A; TREAT Asia HIV Observational Database of IeDEA Asia-Pacific. Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV. HIV Med 2021. [PMID: 34816562 DOI: 10.1111/hiv.13211] [Reference Citation Analysis]
145 Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, Hwang C, Sklar P, Martin EA. Changes in weight and BMI with first-line doravirine-based therapy. AIDS 2021;35:91-9. [PMID: 33048879 DOI: 10.1097/QAD.0000000000002725] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
146 Jaquet A, Muula G, Ekouevi DK, Wandeler G. Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. Curr Epidemiol Rep 2021;8:89-96. [PMID: 34532216 DOI: 10.1007/s40471-021-00273-6] [Reference Citation Analysis]
147 Schafer JJ, Zimmerman M, Walshe C, Cerankowski J, Shimada A, Keith SW. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide. Obesity (Silver Spring) 2022;30:1197-204. [PMID: 35674696 DOI: 10.1002/oby.23443] [Reference Citation Analysis]
148 Christensen BL, Tan DH. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. Expert Opin Pharmacother 2022;:1-8. [PMID: 35073817 DOI: 10.1080/14656566.2022.2029409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, McComsey GA, Palella FJ, Tassiopoulos K, Erlandson KM. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis 2020;71:e471-7. [PMID: 32099991 DOI: 10.1093/cid/ciaa177] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 31.0] [Reference Citation Analysis]
150 Capeau J. Weight and antiretrovirals: a new episode in a long series. Lancet HIV 2021;8:e663-4. [PMID: 34555327 DOI: 10.1016/S2352-3018(21)00189-2] [Reference Citation Analysis]
151 Kouamou V, Inzaule S, Manasa J. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS 2022;36:1053-4. [PMID: 35652678 DOI: 10.1097/QAD.0000000000003221] [Reference Citation Analysis]
152 Vos AG, Venter WDF. Cardiovascular toxicity of contemporary antiretroviral therapy. Curr Opin HIV AIDS 2021;16:286-91. [PMID: 34545036 DOI: 10.1097/COH.0000000000000702] [Reference Citation Analysis]
153 van Genderen JG, Van den Hof M, de Boer CG, Jansen HPG, van Deventer SJH, Tsimikas S, Witztum JL, Kastelein JJP, Pajkrt D. Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents. Viruses 2021;13:2067. [PMID: 34696496 DOI: 10.3390/v13102067] [Reference Citation Analysis]
154 Cindi Z, Maartens G, Bradford Y, Venter WDF, Sokhela S, Chandiwana NC, Haas DW, Sinxadi P. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr 2021;87:1002-9. [PMID: 33625064 DOI: 10.1097/QAI.0000000000002661] [Reference Citation Analysis]
155 Ando N, Nishijima T, Mizushima D, Inaba Y, Kawasaki Y, Kikuchi Y, Oka S, Gatanaga H. Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus. Int J Infect Dis 2021;110:21-8. [PMID: 34273516 DOI: 10.1016/j.ijid.2021.07.030] [Reference Citation Analysis]
156 Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H; GS-US-380–4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis 2021;73:e485-93. [PMID: 32668455 DOI: 10.1093/cid/ciaa988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
157 Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep 2020;17:138-50. [PMID: 32072466 DOI: 10.1007/s11904-020-00483-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
158 Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr Med Res Opin 2020;36:1313-23. [PMID: 32459155 DOI: 10.1080/03007995.2020.1775074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, Esser S, Huang H, Koethe JR, Martin H, McComsey GA, Orkin C, Post FA, Rockstroh JK, Sax PE, Stellbrink HJ, Waters L, Wei X, Lake JE. Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis 2021:ciab444. [PMID: 33987636 DOI: 10.1093/cid/ciab444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
160 Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Curr Med Res Opin 2021;:1-26. [PMID: 34812097 DOI: 10.1080/03007995.2021.2007006] [Reference Citation Analysis]
161 Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopal MN, McDonald C, Blair C, Andreatta K, Collins SE, Brainard DM, Martin H; BRAAVE2020 Investigators. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. J Acquir Immune Defic Syndr 2021;88:86-95. [PMID: 34397746 DOI: 10.1097/QAI.0000000000002731] [Reference Citation Analysis]
162 Taramasso L, Di Biagio A, Bovis F, Forlanini F, Albani E, Papaioannu R, Giacomet V. Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. Microorganisms 2020;8:E864. [PMID: 32521616 DOI: 10.3390/microorganisms8060864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
163 Shah S, Hill A. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Curr Opin Infect Dis 2021;34:16-24. [PMID: 33278177 DOI: 10.1097/QCO.0000000000000695] [Reference Citation Analysis]
164 Burns JE, Stirrup O, Waters L, Dunn D, Gilson R, Pett SL. No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults. HIV Med 2021. [PMID: 34634168 DOI: 10.1111/hiv.13186] [Reference Citation Analysis]
165 McGettrick P, Mallon PWG, Sabin CA. Cardiovascular disease in HIV patients: recent advances in predicting and managing risk. Expert Rev Anti Infect Ther 2020;18:677-88. [PMID: 32306781 DOI: 10.1080/14787210.2020.1757430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Langmia IM, Just KS, Yamoune S, Brockmöller J, Masimirembwa C, Stingl JC. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy. Front Genet 2021;12:692234. [PMID: 34322158 DOI: 10.3389/fgene.2021.692234] [Reference Citation Analysis]
167 Cassenote AJF, Grangeiro A, Escuder MM, Abe JM, Santos RD, Segurado AC. Incidence and associated factors of type 2 diabetes mellitus onset in the Brazilian HIV/AIDS cohort study. Braz J Infect Dis 2021;25:101608. [PMID: 34474003 DOI: 10.1016/j.bjid.2021.101608] [Reference Citation Analysis]
168 Petoumenos K, Kuwanda L, Ryom L, Mocroft A, Reiss P, De Wit S, Pradier C, Bonnet F, Phillips A, Hatleberg CI, d'Arminio Monforte A, Weber R, Sabin CA, Lundgren J, Law MG; for the D:A:D Study Group. Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 2021;86:579-86. [DOI: 10.1097/qai.0000000000002603] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Shafran SD, Di Perri G. Response to Noe, Oldenbuettel and Jaeger. HIV Med 2020;21:e12-3. [PMID: 31852020 DOI: 10.1111/hiv.12835] [Reference Citation Analysis]
170 Prather C, Jeon C. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. Am J Health Syst Pharm 2022:zxac201. [PMID: 35894204 DOI: 10.1093/ajhp/zxac201] [Reference Citation Analysis]
171 Birabaharan M, Strunk A, Kaelber DC, Smith DM, Martin TCS. Sex differences in type 2 diabetes mellitus prevalence among persons with HIV. AIDS 2022;36:383-9. [PMID: 34750292 DOI: 10.1097/QAD.0000000000003127] [Reference Citation Analysis]
172 Saumoy M, Sánchez-Quesada JL, Assoumou L, Gatell JM, González-Cordón A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masiá M, Ordónez-Llanos J, Pozniak A, Martínez E, Podzamczer D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. J Antimicrob Chemother 2022:dkac117. [PMID: 35411401 DOI: 10.1093/jac/dkac117] [Reference Citation Analysis]
173 Hatleberg CI, Ryom L, Sabin C. Cardiovascular risks associated with protease inhibitors for the treatment of HIV. Expert Opin Drug Saf 2021;:1-16. [PMID: 34047238 DOI: 10.1080/14740338.2021.1935863] [Reference Citation Analysis]
174 Shiau S, Bender AA, O'Halloran JA, Sundermann E, Aggarwal J, Althoff KN, Baker JV, Deeks S, Fried LP, Karpiak S, Karris MY, Marcotte TD, Nachega JB, Margolick JB, Erlandson KM, Moore DJ. The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging. AIDS Res Hum Retroviruses 2020;36:973-81. [PMID: 32847368 DOI: 10.1089/AID.2020.0128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
175 Ruiz-Mateos E, Poveda E, Lederman MM. Antiretroviral Treatment for HIV Elite Controllers? Pathog Immun 2020;5:121-33. [PMID: 32582872 DOI: 10.20411/pai.v5i1.364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
176 Martínez-Sanz J, Blanco JR, Muriel A, Pérez-Elías MJ, Rubio-Martín R, Berenguer J, Peraire J, Bernal E, Martínez OJ, Serrano-Villar S, Moreno S; CoRIS. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study. J Int AIDS Soc 2021;24:e25732. [PMID: 34036745 DOI: 10.1002/jia2.25732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G; SHIVER Network. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology 2020;71:1831-44. [PMID: 32052857 DOI: 10.1002/hep.31177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
178 Sapuła M, Suchacz M, Załęski A, Wiercińska-Drapało A. Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review. Viruses 2022;14:122. [PMID: 35062326 DOI: 10.3390/v14010122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
179 Curran A, Rull A, Navarro J, Vidal-González J, Martin-Castillo M, Burgos J, Falcó V, Ribera E, Torrella A, Planas B, Peraire J, Crespo M. Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. J Clin Med 2020;9:E1246. [PMID: 32344934 DOI: 10.3390/jcm9051246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med 2020;21 Suppl 1:3-16. [PMID: 32017355 DOI: 10.1111/hiv.12833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]